Italia markets closed

Dow Jones
39.812,56
+5,79(+0,01%)
Nasdaq
16.799,24
+4,36(+0,03%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0858
-0,0004(-0,03%)
Bitcoin EUR
64.409,22
+1.990,77(+3,19%)
CMC Crypto 200
1.522,85
+34,31(+2,31%)

NVCR Jun 2024 22.500 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,3500

+0,1500

(+12,50%)

In data: 11:40AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in